John Kinsella
Concepts (678)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nitric Oxide | 88 | 2023 | 883 | 7.320 |
Why?
| | Hernias, Diaphragmatic, Congenital | 26 | 2024 | 188 | 5.960 |
Why?
| | Persistent Fetal Circulation Syndrome | 37 | 2023 | 132 | 4.740 |
Why?
| | Hypertension, Pulmonary | 46 | 2025 | 1957 | 3.260 |
Why?
| | Respiratory Insufficiency | 29 | 2023 | 330 | 3.180 |
Why?
| | Extracorporeal Membrane Oxygenation | 30 | 2024 | 370 | 2.840 |
Why?
| | Bronchopulmonary Dysplasia | 19 | 2025 | 427 | 2.490 |
Why?
| | Administration, Inhalation | 70 | 2023 | 567 | 2.320 |
Why?
| | Infant, Newborn | 108 | 2026 | 6460 | 2.050 |
Why?
| | Hemodynamics | 41 | 2025 | 1114 | 1.790 |
Why?
| | Infant, Premature | 31 | 2024 | 622 | 1.700 |
Why?
| | Bronchodilator Agents | 12 | 2020 | 186 | 1.690 |
Why?
| | High-Frequency Ventilation | 20 | 2006 | 44 | 1.660 |
Why?
| | Vasodilator Agents | 15 | 2022 | 326 | 1.550 |
Why?
| | Respiratory Distress Syndrome, Newborn | 13 | 2011 | 104 | 1.540 |
Why?
| | Oxygen Inhalation Therapy | 10 | 2015 | 190 | 1.420 |
Why?
| | Pulmonary Circulation | 31 | 2006 | 431 | 1.300 |
Why?
| | Hernia, Diaphragmatic | 9 | 2021 | 64 | 1.290 |
Why?
| | Infant, Premature, Diseases | 6 | 2019 | 113 | 1.180 |
Why?
| | Ventricular Dysfunction, Left | 4 | 2022 | 391 | 1.140 |
Why?
| | Respiration, Artificial | 25 | 2019 | 711 | 0.970 |
Why?
| | Intensive Care Units | 7 | 2018 | 925 | 0.960 |
Why?
| | Hypoxia | 19 | 2021 | 1211 | 0.930 |
Why?
| | Oxygen | 21 | 2021 | 997 | 0.870 |
Why?
| | Vascular Resistance | 29 | 2021 | 365 | 0.870 |
Why?
| | Echocardiography | 13 | 2023 | 645 | 0.810 |
Why?
| | Blood Gas Analysis | 7 | 2021 | 80 | 0.780 |
Why?
| | Humans | 172 | 2026 | 146342 | 0.780 |
Why?
| | Gestational Age | 22 | 2024 | 990 | 0.750 |
Why?
| | Lung | 33 | 2023 | 4122 | 0.750 |
Why?
| | Transportation of Patients | 3 | 2020 | 62 | 0.730 |
Why?
| | Critical Care | 8 | 2017 | 706 | 0.700 |
Why?
| | Propofol | 5 | 2024 | 86 | 0.680 |
Why?
| | Bronchoconstriction | 1 | 2020 | 29 | 0.640 |
Why?
| | Ventricular Dysfunction | 1 | 2019 | 16 | 0.610 |
Why?
| | Sheep | 40 | 2007 | 870 | 0.610 |
Why?
| | Pulmonary Gas Exchange | 11 | 2009 | 117 | 0.600 |
Why?
| | Pre-Eclampsia | 2 | 2024 | 206 | 0.570 |
Why?
| | Anaphylaxis | 1 | 2020 | 105 | 0.570 |
Why?
| | Heart Atria | 1 | 2020 | 139 | 0.570 |
Why?
| | Fetus | 21 | 2018 | 800 | 0.570 |
Why?
| | Vasodilation | 20 | 2005 | 519 | 0.570 |
Why?
| | Cardiovascular System | 1 | 2020 | 137 | 0.570 |
Why?
| | Ductus Arteriosus, Patent | 4 | 2015 | 49 | 0.560 |
Why?
| | Infant | 36 | 2025 | 10114 | 0.560 |
Why?
| | Severity of Illness Index | 15 | 2025 | 2921 | 0.550 |
Why?
| | Hospital Mortality | 6 | 2018 | 1051 | 0.510 |
Why?
| | Trachea | 2 | 2018 | 253 | 0.510 |
Why?
| | Heart Ventricles | 3 | 2020 | 762 | 0.500 |
Why?
| | Early Medical Intervention | 2 | 2014 | 59 | 0.500 |
Why?
| | Critical Illness | 5 | 2017 | 908 | 0.500 |
Why?
| | Anesthetics, Intravenous | 4 | 2024 | 67 | 0.490 |
Why?
| | Pulmonary Surfactants | 6 | 2021 | 105 | 0.480 |
Why?
| | Liver Cirrhosis | 2 | 2015 | 278 | 0.470 |
Why?
| | Monitoring, Physiologic | 3 | 2019 | 279 | 0.470 |
Why?
| | Animals, Newborn | 18 | 2007 | 888 | 0.470 |
Why?
| | Prenatal Diagnosis | 1 | 2018 | 190 | 0.470 |
Why?
| | Endothelium-Dependent Relaxing Factors | 1 | 2015 | 17 | 0.460 |
Why?
| | Hyaline Membrane Disease | 6 | 1998 | 20 | 0.460 |
Why?
| | Female | 83 | 2026 | 79499 | 0.450 |
Why?
| | Blood Coagulation | 1 | 2017 | 267 | 0.450 |
Why?
| | Pulmonary Artery | 20 | 2021 | 1116 | 0.450 |
Why?
| | Morphine | 1 | 2016 | 171 | 0.440 |
Why?
| | Umbilical Arteries | 1 | 2015 | 51 | 0.440 |
Why?
| | Radial Artery | 1 | 2015 | 74 | 0.440 |
Why?
| | Nerve Block | 1 | 2016 | 114 | 0.430 |
Why?
| | Ultrasonography, Interventional | 1 | 2016 | 163 | 0.430 |
Why?
| | Treatment Outcome | 27 | 2026 | 11821 | 0.430 |
Why?
| | Male | 65 | 2025 | 73396 | 0.410 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2016 | 193 | 0.400 |
Why?
| | Superoxide Dismutase | 2 | 2006 | 307 | 0.400 |
Why?
| | Vitamin A | 1 | 2013 | 60 | 0.390 |
Why?
| | Oxygen Consumption | 3 | 2015 | 721 | 0.390 |
Why?
| | Practice Guidelines as Topic | 3 | 2020 | 1591 | 0.390 |
Why?
| | Knowledge Bases | 1 | 2013 | 28 | 0.380 |
Why?
| | Vitamins | 1 | 2013 | 183 | 0.360 |
Why?
| | Phosphodiesterase Inhibitors | 5 | 2013 | 73 | 0.350 |
Why?
| | Alcohol-Related Disorders | 1 | 2013 | 125 | 0.340 |
Why?
| | Intestinal Obstruction | 1 | 2012 | 54 | 0.340 |
Why?
| | Retrospective Studies | 27 | 2024 | 17438 | 0.330 |
Why?
| | Muscle, Smooth, Vascular | 8 | 2005 | 449 | 0.330 |
Why?
| | Anesthesia, General | 2 | 2005 | 124 | 0.320 |
Why?
| | Lung Diseases | 6 | 2010 | 787 | 0.310 |
Why?
| | Paresis | 1 | 2010 | 30 | 0.310 |
Why?
| | Sulfones | 4 | 2013 | 127 | 0.300 |
Why?
| | Adrenal Insufficiency | 1 | 2010 | 31 | 0.300 |
Why?
| | Emergency Medicine | 1 | 2013 | 280 | 0.300 |
Why?
| | Dietary Supplements | 1 | 2013 | 587 | 0.290 |
Why?
| | Nitric Oxide Synthase | 15 | 2005 | 233 | 0.290 |
Why?
| | Survival Rate | 14 | 2022 | 2092 | 0.280 |
Why?
| | Decision Support Systems, Clinical | 1 | 2013 | 279 | 0.280 |
Why?
| | Dipyridamole | 6 | 1998 | 28 | 0.280 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2010 | 216 | 0.280 |
Why?
| | Herniorrhaphy | 2 | 2020 | 87 | 0.270 |
Why?
| | Pacemaker, Artificial | 1 | 2009 | 127 | 0.270 |
Why?
| | Nose | 2 | 2008 | 67 | 0.270 |
Why?
| | Meconium Aspiration Syndrome | 3 | 2003 | 11 | 0.260 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2011 | 295 | 0.260 |
Why?
| | Fluorocarbons | 2 | 1999 | 122 | 0.260 |
Why?
| | Analgesics, Opioid | 1 | 2016 | 1221 | 0.260 |
Why?
| | Pregnancy | 20 | 2026 | 7230 | 0.250 |
Why?
| | Heart Rate, Fetal | 3 | 2026 | 31 | 0.250 |
Why?
| | Cardiac Output | 8 | 2009 | 176 | 0.250 |
Why?
| | Heart Defects, Congenital | 7 | 2022 | 923 | 0.250 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2007 | 117 | 0.250 |
Why?
| | Foreign Bodies | 1 | 2008 | 109 | 0.240 |
Why?
| | Action Potentials | 1 | 2010 | 500 | 0.240 |
Why?
| | Child | 22 | 2025 | 22693 | 0.240 |
Why?
| | Anticoagulants | 2 | 2024 | 746 | 0.230 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3926 | 0.230 |
Why?
| | Pulmonary Alveoli | 4 | 2022 | 385 | 0.230 |
Why?
| | Thyroidectomy | 2 | 2024 | 97 | 0.230 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2013 | 928 | 0.230 |
Why?
| | Atrioventricular Block | 1 | 2026 | 44 | 0.230 |
Why?
| | Bradycardia | 1 | 2026 | 63 | 0.230 |
Why?
| | Animals | 60 | 2022 | 38107 | 0.230 |
Why?
| | Fetal Diseases | 3 | 2026 | 192 | 0.230 |
Why?
| | Piperazines | 3 | 2013 | 368 | 0.220 |
Why?
| | Respiration Disorders | 1 | 2005 | 78 | 0.210 |
Why?
| | Hirudins | 1 | 2024 | 52 | 0.210 |
Why?
| | Respiration | 3 | 2019 | 208 | 0.210 |
Why?
| | Muscle Stretching Exercises | 1 | 2024 | 18 | 0.210 |
Why?
| | Tracheostomy | 2 | 2024 | 136 | 0.210 |
Why?
| | Antithrombins | 1 | 2024 | 71 | 0.200 |
Why?
| | Neck Pain | 1 | 2024 | 35 | 0.200 |
Why?
| | Ventricular Function, Left | 6 | 2020 | 541 | 0.200 |
Why?
| | Postoperative Hemorrhage | 1 | 2024 | 106 | 0.200 |
Why?
| | Heart | 3 | 2019 | 626 | 0.200 |
Why?
| | Ductus Arteriosus | 11 | 2005 | 71 | 0.190 |
Why?
| | Preoperative Care | 3 | 2017 | 396 | 0.190 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2020 | 2022 | 0.190 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2024 | 69 | 0.190 |
Why?
| | Heparin | 1 | 2024 | 247 | 0.190 |
Why?
| | Fatal Outcome | 4 | 2012 | 302 | 0.190 |
Why?
| | Double-Blind Method | 4 | 2016 | 2070 | 0.190 |
Why?
| | Nitrites | 1 | 2002 | 85 | 0.180 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2017 | 74 | 0.180 |
Why?
| | Antioxidants | 1 | 2006 | 544 | 0.180 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 232 | 0.180 |
Why?
| | Prospective Studies | 11 | 2023 | 8123 | 0.180 |
Why?
| | Respiratory Therapy | 3 | 2003 | 25 | 0.180 |
Why?
| | Risk Factors | 12 | 2024 | 10921 | 0.170 |
Why?
| | Incidence | 5 | 2015 | 2936 | 0.170 |
Why?
| | Prognosis | 7 | 2023 | 4351 | 0.170 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2001 | 39 | 0.170 |
Why?
| | Vasoconstriction | 3 | 2005 | 216 | 0.160 |
Why?
| | Precision Medicine | 2 | 2023 | 462 | 0.160 |
Why?
| | Peptide Fragments | 1 | 2024 | 693 | 0.160 |
Why?
| | Emergency Treatment | 1 | 2002 | 122 | 0.160 |
Why?
| | Fundoplication | 1 | 2020 | 49 | 0.160 |
Why?
| | Plethysmography | 1 | 2001 | 104 | 0.160 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 543 | 0.160 |
Why?
| | Cardiac Catheterization | 7 | 2025 | 571 | 0.160 |
Why?
| | Neuromuscular Nondepolarizing Agents | 1 | 2020 | 34 | 0.160 |
Why?
| | Papio | 6 | 1995 | 71 | 0.160 |
Why?
| | Therapy, Computer-Assisted | 1 | 2020 | 55 | 0.150 |
Why?
| | Blood Pressure | 13 | 2014 | 1765 | 0.150 |
Why?
| | Carbon Monoxide | 1 | 2000 | 82 | 0.150 |
Why?
| | Fluid Therapy | 2 | 2011 | 154 | 0.150 |
Why?
| | Time Factors | 12 | 2017 | 7109 | 0.150 |
Why?
| | Logistic Models | 6 | 2024 | 2126 | 0.150 |
Why?
| | Middle Aged | 19 | 2019 | 36619 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2019 | 1763 | 0.140 |
Why?
| | Infusions, Intravenous | 4 | 2024 | 432 | 0.140 |
Why?
| | Thrombelastography | 1 | 2020 | 182 | 0.140 |
Why?
| | Pulmonary Veins | 2 | 1999 | 110 | 0.140 |
Why?
| | Postoperative Complications | 6 | 2017 | 3034 | 0.140 |
Why?
| | Patient Care Team | 2 | 2016 | 701 | 0.140 |
Why?
| | Neoplasm Staging | 3 | 2018 | 1488 | 0.140 |
Why?
| | Combined Modality Therapy | 7 | 2017 | 1271 | 0.140 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2113 | 0.140 |
Why?
| | Treatment Failure | 5 | 2007 | 361 | 0.140 |
Why?
| | Risk | 3 | 2021 | 920 | 0.130 |
Why?
| | Aged | 15 | 2019 | 26432 | 0.130 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 190 | 0.130 |
Why?
| | United Kingdom | 3 | 2017 | 377 | 0.130 |
Why?
| | Child, Preschool | 15 | 2025 | 11913 | 0.130 |
Why?
| | Return to Work | 1 | 2017 | 21 | 0.130 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 91 | 0.130 |
Why?
| | Single-Blind Method | 2 | 2013 | 313 | 0.130 |
Why?
| | Adult | 19 | 2026 | 41087 | 0.130 |
Why?
| | Heart Rate | 4 | 2009 | 846 | 0.130 |
Why?
| | Cerebral Hemorrhage | 2 | 2014 | 125 | 0.130 |
Why?
| | Abnormalities, Multiple | 1 | 2019 | 195 | 0.130 |
Why?
| | Thiopental | 1 | 1997 | 13 | 0.130 |
Why?
| | Ondansetron | 1 | 1997 | 19 | 0.120 |
Why?
| | Pneumonectomy | 1 | 2019 | 169 | 0.120 |
Why?
| | Troponin I | 1 | 2017 | 74 | 0.120 |
Why?
| | Retinopathy of Prematurity | 1 | 2019 | 183 | 0.120 |
Why?
| | Registries | 6 | 2025 | 2400 | 0.120 |
Why?
| | Pulmonary Edema | 1 | 1997 | 105 | 0.120 |
Why?
| | Anesthesia, Spinal | 1 | 2016 | 13 | 0.120 |
Why?
| | Methemoglobin | 2 | 1993 | 24 | 0.120 |
Why?
| | Intubation, Intratracheal | 2 | 2018 | 330 | 0.120 |
Why?
| | Blood Circulation | 3 | 1998 | 43 | 0.120 |
Why?
| | Smoke Inhalation Injury | 3 | 1991 | 29 | 0.120 |
Why?
| | Biological Products | 1 | 2000 | 258 | 0.120 |
Why?
| | Dyspnea | 1 | 2018 | 251 | 0.120 |
Why?
| | Capillary Permeability | 1 | 1997 | 133 | 0.120 |
Why?
| | Anesthesia, Local | 1 | 2016 | 27 | 0.120 |
Why?
| | Glycocalyx | 1 | 2016 | 30 | 0.120 |
Why?
| | Follow-Up Studies | 10 | 2019 | 5439 | 0.120 |
Why?
| | Injections, Spinal | 1 | 2016 | 120 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2018 | 267 | 0.120 |
Why?
| | Antiemetics | 1 | 1997 | 51 | 0.120 |
Why?
| | Infant, Newborn, Diseases | 2 | 2014 | 113 | 0.120 |
Why?
| | Estradiol | 4 | 2001 | 517 | 0.120 |
Why?
| | Multivariate Analysis | 3 | 2016 | 1543 | 0.120 |
Why?
| | Echocardiography, Doppler | 2 | 2001 | 117 | 0.120 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 14 | 0.120 |
Why?
| | Mentors | 1 | 2018 | 217 | 0.120 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 11 | 0.120 |
Why?
| | Disease Management | 2 | 2017 | 651 | 0.120 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2019 | 248 | 0.120 |
Why?
| | Survivors | 1 | 2019 | 526 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 731 | 0.110 |
Why?
| | Employment | 1 | 2017 | 180 | 0.110 |
Why?
| | Thyroid Carcinoma, Anaplastic | 1 | 2016 | 37 | 0.110 |
Why?
| | Nitroarginine | 10 | 2005 | 56 | 0.110 |
Why?
| | Emergency Service, Hospital | 1 | 2008 | 2363 | 0.110 |
Why?
| | Colorectal Neoplasms | 2 | 2016 | 874 | 0.110 |
Why?
| | Down Syndrome | 1 | 2022 | 529 | 0.110 |
Why?
| | Chronic Disease | 8 | 2013 | 1827 | 0.110 |
Why?
| | Neutrophils | 3 | 1999 | 1133 | 0.110 |
Why?
| | Radiography | 2 | 2008 | 861 | 0.110 |
Why?
| | Length of Stay | 5 | 2017 | 1358 | 0.110 |
Why?
| | Surgical Procedures, Operative | 1 | 2018 | 307 | 0.110 |
Why?
| | Hypnotics and Sedatives | 2 | 2024 | 223 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2018 | 561 | 0.110 |
Why?
| | Faculty, Medical | 1 | 2018 | 309 | 0.110 |
Why?
| | Statistics as Topic | 1 | 2015 | 279 | 0.110 |
Why?
| | Sildenafil Citrate | 4 | 2021 | 60 | 0.110 |
Why?
| | Risk Assessment | 4 | 2017 | 3712 | 0.110 |
Why?
| | Cerebrovascular Circulation | 3 | 1995 | 293 | 0.100 |
Why?
| | Postoperative Care | 1 | 2016 | 301 | 0.100 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2011 | 545 | 0.100 |
Why?
| | Ventilator Weaning | 2 | 2005 | 38 | 0.100 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 365 | 0.100 |
Why?
| | Ammonia | 2 | 1992 | 61 | 0.100 |
Why?
| | Mothers | 1 | 2020 | 772 | 0.100 |
Why?
| | Vasopressins | 1 | 2014 | 60 | 0.100 |
Why?
| | Continuity of Patient Care | 1 | 2016 | 298 | 0.100 |
Why?
| | Biomarkers | 4 | 2016 | 4340 | 0.100 |
Why?
| | Thrombosis | 1 | 2017 | 398 | 0.100 |
Why?
| | Pediatrics | 2 | 2019 | 1124 | 0.100 |
Why?
| | Vasoconstrictor Agents | 1 | 2014 | 148 | 0.100 |
Why?
| | Alcohol Withdrawal Delirium | 1 | 2013 | 9 | 0.100 |
Why?
| | Survival Analysis | 3 | 2009 | 1378 | 0.100 |
Why?
| | Hypotension | 1 | 2014 | 125 | 0.090 |
Why?
| | Elective Surgical Procedures | 2 | 2011 | 216 | 0.090 |
Why?
| | Clinical Trials as Topic | 3 | 2008 | 1064 | 0.090 |
Why?
| | Epoprostenol | 3 | 2021 | 132 | 0.090 |
Why?
| | Cyclic GMP | 4 | 2001 | 88 | 0.090 |
Why?
| | Cell Nucleus | 1 | 1996 | 584 | 0.090 |
Why?
| | Coronary Circulation | 2 | 1995 | 134 | 0.090 |
Why?
| | Pilot Projects | 5 | 2024 | 1888 | 0.090 |
Why?
| | Diaphragm | 2 | 2023 | 45 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2016 | 461 | 0.090 |
Why?
| | Critical Care Nursing | 1 | 2013 | 48 | 0.090 |
Why?
| | Vascular Diseases | 1 | 2015 | 252 | 0.090 |
Why?
| | Hemorrhage | 1 | 2017 | 825 | 0.090 |
Why?
| | Early Diagnosis | 1 | 2013 | 251 | 0.090 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2011 | 9 | 0.090 |
Why?
| | Recombinant Proteins | 2 | 2024 | 1361 | 0.090 |
Why?
| | Delivery Rooms | 1 | 2011 | 11 | 0.080 |
Why?
| | Aged, 80 and over | 4 | 2017 | 8391 | 0.080 |
Why?
| | Diseases in Twins | 1 | 2012 | 115 | 0.080 |
Why?
| | Kidney Tubules | 1 | 1992 | 117 | 0.080 |
Why?
| | Troponin | 1 | 2011 | 50 | 0.080 |
Why?
| | Ventilators, Mechanical | 2 | 2016 | 70 | 0.080 |
Why?
| | Cohort Studies | 5 | 2024 | 6077 | 0.080 |
Why?
| | Acetylcholine | 5 | 2001 | 209 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2018 | 3647 | 0.080 |
Why?
| | Respiratory Mechanics | 3 | 1999 | 74 | 0.080 |
Why?
| | Cardiac Output, Low | 1 | 1991 | 53 | 0.080 |
Why?
| | Algorithms | 3 | 2013 | 1849 | 0.080 |
Why?
| | Patient Admission | 1 | 2013 | 216 | 0.080 |
Why?
| | Alfentanil | 1 | 2010 | 7 | 0.080 |
Why?
| | Monitoring, Intraoperative | 2 | 2008 | 66 | 0.080 |
Why?
| | Nitric Oxide Synthase Type III | 7 | 2007 | 199 | 0.080 |
Why?
| | Oocyte Retrieval | 1 | 2010 | 20 | 0.080 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 189 | 0.080 |
Why?
| | Delivery, Obstetric | 1 | 1991 | 164 | 0.080 |
Why?
| | DNA-Binding Proteins | 2 | 2007 | 1468 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2011 | 176 | 0.080 |
Why?
| | Thermodilution | 2 | 2005 | 16 | 0.080 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 242 | 0.080 |
Why?
| | Disease Models, Animal | 7 | 2007 | 4580 | 0.080 |
Why?
| | Endothelium, Vascular | 5 | 2016 | 952 | 0.080 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2003 | 85 | 0.070 |
Why?
| | APACHE | 2 | 2017 | 67 | 0.070 |
Why?
| | Communication | 1 | 2016 | 980 | 0.070 |
Why?
| | Physicians | 1 | 2018 | 955 | 0.070 |
Why?
| | Airway Obstruction | 1 | 1991 | 152 | 0.070 |
Why?
| | Analysis of Variance | 6 | 2014 | 1298 | 0.070 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.070 |
Why?
| | Endothelin Receptor Antagonists | 3 | 1998 | 60 | 0.070 |
Why?
| | Endothelins | 3 | 2000 | 61 | 0.070 |
Why?
| | Vitamin D | 1 | 2012 | 402 | 0.070 |
Why?
| | Positive-Pressure Respiration | 2 | 2000 | 115 | 0.070 |
Why?
| | Prostaglandins | 2 | 2001 | 94 | 0.070 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 98 | 0.070 |
Why?
| | Anesthetics, Combined | 1 | 2008 | 7 | 0.070 |
Why?
| | Regional Blood Flow | 4 | 1998 | 507 | 0.070 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 486 | 0.070 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 185 | 0.070 |
Why?
| | Patient Readmission | 1 | 2013 | 778 | 0.070 |
Why?
| | Chest Wall Oscillation | 1 | 2007 | 5 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2475 | 0.070 |
Why?
| | Scotland | 2 | 2018 | 54 | 0.070 |
Why?
| | Hydrocortisone | 1 | 2010 | 303 | 0.060 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2011 | 334 | 0.060 |
Why?
| | Transcription Factors | 1 | 1996 | 1730 | 0.060 |
Why?
| | Receptors, Endothelin | 3 | 2000 | 46 | 0.060 |
Why?
| | Postoperative Period | 3 | 2016 | 355 | 0.060 |
Why?
| | Acute Disease | 2 | 2005 | 1038 | 0.060 |
Why?
| | Sex Distribution | 1 | 2008 | 382 | 0.060 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 2 | 1998 | 17 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 2 | 2004 | 109 | 0.060 |
Why?
| | Microspheres | 3 | 1991 | 142 | 0.060 |
Why?
| | Lung Neoplasms | 2 | 2019 | 2675 | 0.060 |
Why?
| | Leukomalacia, Periventricular | 1 | 2006 | 9 | 0.060 |
Why?
| | Purines | 3 | 2013 | 188 | 0.060 |
Why?
| | Piperidines | 1 | 2008 | 225 | 0.060 |
Why?
| | Neoplasms | 2 | 2019 | 2954 | 0.060 |
Why?
| | Endothelin-1 | 5 | 2000 | 177 | 0.060 |
Why?
| | Swine | 2 | 2003 | 821 | 0.060 |
Why?
| | Umbilical Cord | 1 | 2026 | 92 | 0.060 |
Why?
| | Atrial Natriuretic Factor | 2 | 1996 | 54 | 0.060 |
Why?
| | Intracranial Hemorrhages | 1 | 2006 | 106 | 0.060 |
Why?
| | Enzyme Inhibitors | 7 | 2005 | 823 | 0.060 |
Why?
| | Lung Compliance | 1 | 2005 | 43 | 0.060 |
Why?
| | Methyl Ethers | 1 | 2005 | 19 | 0.060 |
Why?
| | Epinephrine | 1 | 2026 | 160 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 1998 | 615 | 0.060 |
Why?
| | Airway Resistance | 1 | 2005 | 38 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 35 | 0.060 |
Why?
| | Prenatal Care | 1 | 2007 | 310 | 0.050 |
Why?
| | Signal Transduction | 3 | 2005 | 5246 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2010 | 1160 | 0.050 |
Why?
| | Electric Impedance | 1 | 2005 | 108 | 0.050 |
Why?
| | Anesthetics, Inhalation | 1 | 2005 | 52 | 0.050 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 299 | 0.050 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2022 | 66 | 0.050 |
Why?
| | Amides | 1 | 2005 | 100 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2006 | 3017 | 0.050 |
Why?
| | Drug Administration Schedule | 4 | 2011 | 790 | 0.050 |
Why?
| | Carbon Dioxide | 4 | 1999 | 228 | 0.050 |
Why?
| | Electroencephalography | 1 | 2008 | 576 | 0.050 |
Why?
| | Aging | 2 | 1992 | 1996 | 0.050 |
Why?
| | Rats | 7 | 2005 | 5586 | 0.050 |
Why?
| | Cesarean Section | 1 | 2026 | 230 | 0.050 |
Why?
| | Carcinoma | 2 | 2016 | 225 | 0.050 |
Why?
| | Home Nursing | 1 | 2003 | 24 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1408 | 0.050 |
Why?
| | Bronchoalveolar Lavage | 1 | 2003 | 90 | 0.050 |
Why?
| | Cost-Benefit Analysis | 3 | 2011 | 640 | 0.050 |
Why?
| | Birth Weight | 1 | 2006 | 521 | 0.050 |
Why?
| | Esophagus | 1 | 2005 | 260 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2005 | 269 | 0.050 |
Why?
| | Endothelial Growth Factors | 1 | 2002 | 61 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2024 | 297 | 0.050 |
Why?
| | Forced Expiratory Volume | 2 | 2016 | 451 | 0.050 |
Why?
| | Embryonic and Fetal Development | 3 | 2000 | 90 | 0.050 |
Why?
| | Lymphokines | 1 | 2002 | 127 | 0.050 |
Why?
| | Intermittent Positive-Pressure Ventilation | 2 | 1993 | 12 | 0.050 |
Why?
| | Surgical Flaps | 1 | 2023 | 140 | 0.050 |
Why?
| | Age Factors | 3 | 2016 | 3347 | 0.040 |
Why?
| | Mouth Mucosa | 1 | 2022 | 84 | 0.040 |
Why?
| | Stomach | 1 | 2002 | 106 | 0.040 |
Why?
| | Sequence Deletion | 1 | 2022 | 190 | 0.040 |
Why?
| | Mosaicism | 1 | 2022 | 67 | 0.040 |
Why?
| | Analgesics | 1 | 2024 | 230 | 0.040 |
Why?
| | Evaluation Studies as Topic | 2 | 1992 | 161 | 0.040 |
Why?
| | Estrogen Antagonists | 1 | 2001 | 37 | 0.040 |
Why?
| | Phenotype | 2 | 2023 | 3206 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2022 | 209 | 0.040 |
Why?
| | Thyroid Neoplasms | 2 | 2016 | 380 | 0.040 |
Why?
| | Uterus | 1 | 2002 | 227 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5899 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2002 | 372 | 0.040 |
Why?
| | Muscle, Smooth | 2 | 2000 | 152 | 0.040 |
Why?
| | Milrinone | 1 | 2021 | 26 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2001 | 67 | 0.040 |
Why?
| | Ligation | 5 | 2002 | 88 | 0.040 |
Why?
| | Calibration | 1 | 2001 | 154 | 0.040 |
Why?
| | Injections, Intra-Arterial | 1 | 2000 | 25 | 0.040 |
Why?
| | Protoporphyrins | 1 | 2000 | 16 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 6073 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 870 | 0.040 |
Why?
| | Hydrocarbons, Brominated | 1 | 1999 | 5 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2019 | 133 | 0.040 |
Why?
| | Blotting, Northern | 4 | 2000 | 197 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2919 | 0.040 |
Why?
| | Potassium Channel Blockers | 1 | 1999 | 47 | 0.040 |
Why?
| | Angiography | 1 | 1999 | 206 | 0.040 |
Why?
| | Adolescent | 8 | 2005 | 22557 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 1999 | 240 | 0.030 |
Why?
| | Patient Transfer | 1 | 2002 | 224 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2001 | 406 | 0.030 |
Why?
| | Blood Vessels | 1 | 2000 | 164 | 0.030 |
Why?
| | Digestive System Physiological Phenomena | 1 | 1998 | 5 | 0.030 |
Why?
| | Leukocyte Count | 2 | 1997 | 321 | 0.030 |
Why?
| | Drug Synergism | 2 | 1998 | 354 | 0.030 |
Why?
| | Acidosis | 2 | 1992 | 105 | 0.030 |
Why?
| | Asphyxia Neonatorum | 1 | 1998 | 20 | 0.030 |
Why?
| | Esophageal Neoplasms | 1 | 2002 | 351 | 0.030 |
Why?
| | Body Weight | 2 | 2005 | 968 | 0.030 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 1998 | 54 | 0.030 |
Why?
| | Immunohistochemistry | 4 | 2005 | 1712 | 0.030 |
Why?
| | Receptor, Endothelin A | 4 | 2000 | 60 | 0.030 |
Why?
| | Occipital Bone | 1 | 1997 | 18 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2002 | 628 | 0.030 |
Why?
| | Frontal Bone | 1 | 1997 | 19 | 0.030 |
Why?
| | Cephalometry | 1 | 1997 | 30 | 0.030 |
Why?
| | Potassium Channels | 1 | 1998 | 149 | 0.030 |
Why?
| | Growth | 1 | 1997 | 48 | 0.030 |
Why?
| | Disease Progression | 2 | 2017 | 2867 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 1998 | 2838 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2017 | 143 | 0.030 |
Why?
| | Arterial Pressure | 1 | 2017 | 130 | 0.030 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2016 | 23 | 0.030 |
Why?
| | Syndecan-1 | 1 | 2016 | 42 | 0.030 |
Why?
| | Expectorants | 1 | 2016 | 22 | 0.030 |
Why?
| | Arteriovenous Shunt, Surgical | 1 | 2016 | 21 | 0.030 |
Why?
| | Nausea | 1 | 1997 | 111 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 1997 | 195 | 0.030 |
Why?
| | Endothelin-3 | 1 | 1996 | 3 | 0.030 |
Why?
| | Arginine | 2 | 1994 | 264 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2019 | 300 | 0.030 |
Why?
| | Rats, Inbred Strains | 3 | 1992 | 316 | 0.030 |
Why?
| | Interferon-Stimulated Gene Factor 3 | 1 | 1996 | 1 | 0.030 |
Why?
| | Vascular Patency | 1 | 2016 | 115 | 0.030 |
Why?
| | Ireland | 1 | 2016 | 33 | 0.030 |
Why?
| | Arteriovenous Fistula | 1 | 2016 | 36 | 0.030 |
Why?
| | Body Height | 1 | 1997 | 205 | 0.030 |
Why?
| | Interrupted Time Series Analysis | 1 | 2016 | 73 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1996 | 38 | 0.030 |
Why?
| | Vomiting | 1 | 1997 | 131 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2017 | 282 | 0.030 |
Why?
| | Kidney | 3 | 1991 | 1498 | 0.030 |
Why?
| | Patient Selection | 1 | 2000 | 728 | 0.030 |
Why?
| | Gastrostomy | 1 | 1997 | 124 | 0.030 |
Why?
| | Substance Withdrawal Syndrome | 1 | 1998 | 185 | 0.030 |
Why?
| | Blotting, Western | 3 | 2005 | 1177 | 0.030 |
Why?
| | Luciferases | 1 | 1996 | 153 | 0.030 |
Why?
| | Stroke Volume | 1 | 2019 | 652 | 0.030 |
Why?
| | Steroids | 1 | 2016 | 160 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1999 | 1503 | 0.030 |
Why?
| | Enteral Nutrition | 1 | 1997 | 212 | 0.030 |
Why?
| | Tyrosine | 1 | 1996 | 217 | 0.030 |
Why?
| | Genes, Reporter | 1 | 1996 | 275 | 0.030 |
Why?
| | Genetic Counseling | 1 | 2015 | 82 | 0.030 |
Why?
| | Lung Injury | 2 | 2011 | 263 | 0.030 |
Why?
| | Indiana | 1 | 2015 | 38 | 0.030 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2015 | 62 | 0.030 |
Why?
| | Nitric Oxide Synthase Type II | 3 | 2001 | 162 | 0.030 |
Why?
| | Peptides, Cyclic | 4 | 1998 | 276 | 0.030 |
Why?
| | Biological Transport | 3 | 1991 | 424 | 0.030 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2001 | 665 | 0.030 |
Why?
| | Base Sequence | 2 | 1996 | 2123 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 1997 | 329 | 0.030 |
Why?
| | Endothelium | 1 | 1995 | 119 | 0.030 |
Why?
| | Primary Prevention | 1 | 2016 | 222 | 0.030 |
Why?
| | Aorta | 4 | 1998 | 440 | 0.030 |
Why?
| | Cardiovascular Agents | 1 | 2015 | 165 | 0.030 |
Why?
| | Organ Dysfunction Scores | 1 | 2014 | 55 | 0.030 |
Why?
| | Costs and Cost Analysis | 2 | 2009 | 217 | 0.030 |
Why?
| | Vasomotor System | 3 | 2002 | 47 | 0.030 |
Why?
| | Self Efficacy | 1 | 2017 | 418 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2015 | 154 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 693 | 0.030 |
Why?
| | Blood Flow Velocity | 2 | 1992 | 419 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 1996 | 369 | 0.020 |
Why?
| | Life Support Care | 1 | 2014 | 44 | 0.020 |
Why?
| | Drug Evaluation | 1 | 1993 | 78 | 0.020 |
Why?
| | Schools, Medical | 1 | 2015 | 158 | 0.020 |
Why?
| | Area Under Curve | 1 | 2014 | 335 | 0.020 |
Why?
| | Stress, Mechanical | 3 | 2001 | 497 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1992 | 1041 | 0.020 |
Why?
| | Asthma | 1 | 2005 | 1800 | 0.020 |
Why?
| | Reference Values | 3 | 2002 | 796 | 0.020 |
Why?
| | Hypertension | 1 | 2002 | 1272 | 0.020 |
Why?
| | Acute Lung Injury | 1 | 2016 | 312 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 663 | 0.020 |
Why?
| | DNA | 2 | 1998 | 1421 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 340 | 0.020 |
Why?
| | Lactic Acid | 1 | 2014 | 295 | 0.020 |
Why?
| | Young Adult | 1 | 2009 | 14330 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 1997 | 519 | 0.020 |
Why?
| | Prevalence | 1 | 2019 | 2861 | 0.020 |
Why?
| | Ammonium Chloride | 1 | 1992 | 4 | 0.020 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2012 | 74 | 0.020 |
Why?
| | Brain Chemistry | 1 | 1992 | 122 | 0.020 |
Why?
| | Child Development | 1 | 1997 | 481 | 0.020 |
Why?
| | ROC Curve | 1 | 2014 | 617 | 0.020 |
Why?
| | Nephrons | 1 | 1992 | 23 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2015 | 326 | 0.020 |
Why?
| | United States | 3 | 2012 | 16136 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 993 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1864 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2011 | 43 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 208 | 0.020 |
Why?
| | Brain | 2 | 1997 | 2991 | 0.020 |
Why?
| | Streptococcus agalactiae | 1 | 1993 | 118 | 0.020 |
Why?
| | Quality of Life | 2 | 2017 | 3200 | 0.020 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 2 | 2001 | 76 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 1995 | 377 | 0.020 |
Why?
| | Odds Ratio | 1 | 2014 | 1077 | 0.020 |
Why?
| | Phosphorylation | 1 | 1996 | 1724 | 0.020 |
Why?
| | Carboxyhemoglobin | 1 | 1991 | 7 | 0.020 |
Why?
| | Radioisotopes | 1 | 1991 | 37 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1242 | 0.020 |
Why?
| | Body Constitution | 1 | 1991 | 51 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 1993 | 179 | 0.020 |
Why?
| | Patient Discharge | 1 | 2017 | 997 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2003 | 151 | 0.020 |
Why?
| | Models, Cardiovascular | 1 | 1992 | 194 | 0.020 |
Why?
| | Ultrasonography | 1 | 2015 | 788 | 0.020 |
Why?
| | Echovirus Infections | 1 | 1990 | 1 | 0.020 |
Why?
| | Sex Factors | 1 | 2016 | 2107 | 0.020 |
Why?
| | Enterovirus B, Human | 1 | 1990 | 25 | 0.020 |
Why?
| | Intensive Care Units, Pediatric | 1 | 1993 | 293 | 0.020 |
Why?
| | RNA, Messenger | 3 | 2007 | 2791 | 0.020 |
Why?
| | Preoperative Period | 1 | 2010 | 157 | 0.020 |
Why?
| | Meningoencephalitis | 1 | 1990 | 24 | 0.020 |
Why?
| | Medical Audit | 1 | 2010 | 78 | 0.020 |
Why?
| | Guanidines | 2 | 2001 | 39 | 0.020 |
Why?
| | Isoenzymes | 2 | 2001 | 294 | 0.020 |
Why?
| | Burns | 2 | 1991 | 365 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2009 | 129 | 0.020 |
Why?
| | Cyclooxygenase Inhibitors | 2 | 2001 | 82 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 131 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 399 | 0.020 |
Why?
| | Tetraethylammonium | 2 | 1999 | 16 | 0.020 |
Why?
| | Pressure | 2 | 2002 | 221 | 0.020 |
Why?
| | 4-Aminopyridine | 2 | 1999 | 30 | 0.020 |
Why?
| | Heart Diseases | 1 | 1992 | 343 | 0.020 |
Why?
| | Macrophages, Alveolar | 1 | 1991 | 377 | 0.020 |
Why?
| | Constriction | 2 | 1999 | 45 | 0.020 |
Why?
| | Cells, Cultured | 1 | 1996 | 4118 | 0.020 |
Why?
| | Immunologic Techniques | 2 | 1999 | 36 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 2007 | 9 | 0.020 |
Why?
| | Organ Size | 2 | 2005 | 465 | 0.020 |
Why?
| | Receptor, Endothelin B | 2 | 2000 | 43 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 999 | 0.020 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2007 | 27 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 1990 | 642 | 0.020 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 46 | 0.020 |
Why?
| | Protein Precursors | 2 | 2000 | 127 | 0.020 |
Why?
| | Developmental Disabilities | 1 | 2009 | 281 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 866 | 0.010 |
Why?
| | RNA, Viral | 1 | 1990 | 693 | 0.010 |
Why?
| | Proteins | 1 | 1992 | 1022 | 0.010 |
Why?
| | Comorbidity | 1 | 2010 | 1665 | 0.010 |
Why?
| | Thoracic Diseases | 1 | 2005 | 11 | 0.010 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1987 | 198 | 0.010 |
Why?
| | Respiratory Muscles | 1 | 2005 | 36 | 0.010 |
Why?
| | Phosphates | 1 | 1986 | 175 | 0.010 |
Why?
| | Oscillometry | 1 | 2005 | 35 | 0.010 |
Why?
| | Manometry | 1 | 2005 | 96 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 87 | 0.010 |
Why?
| | Hypertrophy | 1 | 2005 | 127 | 0.010 |
Why?
| | Muscular Diseases | 1 | 2005 | 110 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4595 | 0.010 |
Why?
| | Pulse Therapy, Drug | 1 | 2003 | 7 | 0.010 |
Why?
| | Drug Combinations | 1 | 2005 | 400 | 0.010 |
Why?
| | Research Design | 1 | 2010 | 1143 | 0.010 |
Why?
| | Time | 1 | 2003 | 85 | 0.010 |
Why?
| | Administration, Intranasal | 1 | 2003 | 95 | 0.010 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 974 | 0.010 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 2002 | 4 | 0.010 |
Why?
| | Pharyngectomy | 1 | 2002 | 4 | 0.010 |
Why?
| | Speech, Alaryngeal | 1 | 2002 | 3 | 0.010 |
Why?
| | Homeodomain Proteins | 1 | 2007 | 525 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2003 | 32 | 0.010 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2002 | 77 | 0.010 |
Why?
| | Pyrroles | 1 | 2004 | 222 | 0.010 |
Why?
| | Laryngectomy | 1 | 2002 | 17 | 0.010 |
Why?
| | Carrier Proteins | 1 | 1987 | 728 | 0.010 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2003 | 54 | 0.010 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2002 | 83 | 0.010 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2002 | 57 | 0.010 |
Why?
| | Nifedipine | 1 | 2002 | 27 | 0.010 |
Why?
| | Meclofenamic Acid | 1 | 2001 | 9 | 0.010 |
Why?
| | 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2001 | 18 | 0.010 |
Why?
| | Glucocorticoids | 1 | 1986 | 536 | 0.010 |
Why?
| | Cyclooxygenase 1 | 1 | 2001 | 27 | 0.010 |
Why?
| | Oligonucleotides | 1 | 2002 | 155 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 426 | 0.010 |
Why?
| | Clinical Competence | 1 | 2010 | 1272 | 0.010 |
Why?
| | Infusions, Intra-Arterial | 1 | 2001 | 61 | 0.010 |
Why?
| | Electrocardiography | 1 | 2005 | 667 | 0.010 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2001 | 64 | 0.010 |
Why?
| | Lymph Node Excision | 1 | 2002 | 174 | 0.010 |
Why?
| | Esophagectomy | 1 | 2002 | 136 | 0.010 |
Why?
| | Benzylamines | 1 | 2001 | 44 | 0.010 |
Why?
| | Amidines | 1 | 2001 | 14 | 0.010 |
Why?
| | Pulmonary Ventilation | 1 | 2001 | 80 | 0.010 |
Why?
| | Calcium Channel Blockers | 1 | 2002 | 165 | 0.010 |
Why?
| | Calcium Channels | 1 | 2002 | 157 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2001 | 166 | 0.010 |
Why?
| | Organ Specificity | 1 | 2001 | 307 | 0.010 |
Why?
| | Ligands | 1 | 2003 | 678 | 0.010 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2001 | 163 | 0.010 |
Why?
| | Drug Interactions | 1 | 2001 | 405 | 0.010 |
Why?
| | Indoles | 1 | 2004 | 511 | 0.010 |
Why?
| | Calcium | 1 | 1986 | 1181 | 0.010 |
Why?
| | Physical Stimulation | 1 | 2000 | 68 | 0.010 |
Why?
| | Lung Volume Measurements | 1 | 1999 | 44 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2005 | 2537 | 0.010 |
Why?
| | Charybdotoxin | 1 | 1999 | 4 | 0.010 |
Why?
| | Atrial Function, Right | 1 | 1998 | 13 | 0.010 |
Why?
| | Delayed Rectifier Potassium Channels | 1 | 1998 | 9 | 0.010 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 677 | 0.010 |
Why?
| | Shab Potassium Channels | 1 | 1998 | 20 | 0.010 |
Why?
| | Digestive System | 1 | 1998 | 29 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1998 | 86 | 0.010 |
Why?
| | Xenopus | 1 | 1998 | 85 | 0.010 |
Why?
| | Isothiuronium | 1 | 1998 | 3 | 0.010 |
Why?
| | Thiazines | 1 | 1998 | 13 | 0.010 |
Why?
| | Gene Expression | 1 | 2003 | 1463 | 0.010 |
Why?
| | Masks | 1 | 1998 | 70 | 0.010 |
Why?
| | DNA, Complementary | 1 | 1998 | 269 | 0.010 |
Why?
| | Catheterization | 1 | 1998 | 179 | 0.010 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2002 | 902 | 0.010 |
Why?
| | Long-Term Care | 1 | 1998 | 118 | 0.010 |
Why?
| | Medical Records | 1 | 1998 | 193 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1998 | 526 | 0.010 |
Why?
| | Oocytes | 1 | 1998 | 186 | 0.010 |
Why?
| | Methylene Blue | 1 | 1996 | 24 | 0.010 |
Why?
| | Indomethacin | 1 | 1996 | 76 | 0.010 |
Why?
| | Microvilli | 2 | 1987 | 72 | 0.010 |
Why?
| | Dogs | 1 | 1998 | 517 | 0.010 |
Why?
| | Adenosine | 1 | 1998 | 256 | 0.010 |
Why?
| | Staining and Labeling | 1 | 1996 | 148 | 0.010 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 1995 | 8 | 0.010 |
Why?
| | Purinones | 1 | 1995 | 4 | 0.010 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 1995 | 10 | 0.010 |
Why?
| | Cardiomegaly | 1 | 1997 | 175 | 0.010 |
Why?
| | Receptors, Purinergic P1 | 1 | 1995 | 30 | 0.010 |
Why?
| | Theophylline | 1 | 1995 | 41 | 0.010 |
Why?
| | Adenocarcinoma, Follicular | 1 | 1995 | 43 | 0.010 |
Why?
| | Sodium | 2 | 1987 | 196 | 0.010 |
Why?
| | Arterioles | 1 | 1995 | 52 | 0.010 |
Why?
| | Carcinoma, Papillary | 1 | 1995 | 83 | 0.010 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 84 | 0.010 |
Why?
| | Phenylephrine | 1 | 1995 | 74 | 0.010 |
Why?
| | Home Care Services | 1 | 1998 | 293 | 0.010 |
Why?
| | Adrenal Glands | 1 | 1995 | 77 | 0.010 |
Why?
| | Renal Circulation | 1 | 1995 | 75 | 0.010 |
Why?
| | Viper Venoms | 1 | 1994 | 6 | 0.010 |
Why?
| | Muscle Tonus | 1 | 1994 | 24 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 2092 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 504 | 0.010 |
Why?
| | Forecasting | 1 | 1995 | 388 | 0.010 |
Why?
| | Cause of Death | 1 | 1995 | 456 | 0.010 |
Why?
| | Perfusion | 1 | 1994 | 255 | 0.010 |
Why?
| | Intestines | 1 | 1995 | 351 | 0.010 |
Why?
| | Chemotaxis | 1 | 1991 | 121 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 1995 | 565 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1991 | 182 | 0.000 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1990 | 26 | 0.000 |
Why?
| | Agammaglobulinemia | 1 | 1990 | 36 | 0.000 |
Why?
| | Nucleic Acid Hybridization | 1 | 1990 | 175 | 0.000 |
Why?
| | Gene Amplification | 1 | 1990 | 116 | 0.000 |
Why?
| | Cell Count | 1 | 1990 | 315 | 0.000 |
Why?
| | Myocardial Contraction | 1 | 1990 | 292 | 0.000 |
Why?
| | Adenocarcinoma | 1 | 1995 | 927 | 0.000 |
Why?
| | Eosinophils | 1 | 1990 | 319 | 0.000 |
Why?
| | Kidney Cortex | 1 | 1987 | 27 | 0.000 |
Why?
| | Sodium-Hydrogen Exchangers | 1 | 1987 | 23 | 0.000 |
Why?
| | Polymerase Chain Reaction | 1 | 1990 | 1031 | 0.000 |
Why?
| | Monocytes | 1 | 1990 | 538 | 0.000 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1987 | 534 | 0.000 |
Why?
| | Skin | 1 | 1990 | 701 | 0.000 |
Why?
| | Glomerular Filtration Rate | 1 | 1987 | 745 | 0.000 |
Why?
| | Macrophages | 1 | 1990 | 1532 | 0.000 |
Why?
|
|
Kinsella's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|